IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Tomasoni, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.962
AS - Asia 3.877
EU - Europa 1.903
SA - Sud America 946
AF - Africa 114
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.809
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.816
SG - Singapore 1.431
CN - Cina 909
BR - Brasile 791
HK - Hong Kong 546
IT - Italia 525
DE - Germania 321
VN - Vietnam 309
BD - Bangladesh 203
FR - Francia 175
FI - Finlandia 167
RU - Federazione Russa 164
GB - Regno Unito 156
TR - Turchia 137
IN - India 102
CA - Canada 71
IE - Irlanda 71
AR - Argentina 65
UA - Ucraina 64
MX - Messico 42
IQ - Iraq 40
NL - Olanda 40
JP - Giappone 37
ZA - Sudafrica 37
CZ - Repubblica Ceca 35
PL - Polonia 35
SA - Arabia Saudita 31
SE - Svezia 29
PK - Pakistan 28
AT - Austria 27
ES - Italia 24
EC - Ecuador 20
SC - Seychelles 20
CO - Colombia 17
MA - Marocco 16
VE - Venezuela 16
ID - Indonesia 15
KE - Kenya 13
EG - Egitto 11
PE - Perù 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
BE - Belgio 9
LT - Lituania 9
PH - Filippine 9
TN - Tunisia 9
JO - Giordania 8
PY - Paraguay 8
BG - Bulgaria 7
CH - Svizzera 7
CL - Cile 7
JM - Giamaica 7
NP - Nepal 7
LV - Lettonia 6
UY - Uruguay 6
MD - Moldavia 5
PA - Panama 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
HN - Honduras 4
MY - Malesia 4
PS - Palestinian Territory 4
BO - Bolivia 3
CR - Costa Rica 3
CY - Cipro 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
HR - Croazia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
RS - Serbia 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
DZ - Algeria 2
GY - Guiana 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
LB - Libano 2
MK - Macedonia 2
OM - Oman 2
RO - Romania 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
FJ - Figi 1
GR - Grecia 1
HU - Ungheria 1
Totale 10.795
Salva come PNG Salva come JPEG
Città #
Singapore 722
Hong Kong 544
Ashburn 483
San Jose 391
The Dalles 259
Beijing 254
New York 203
Los Angeles 171
Chandler 138
Lauterbourg 134
Helsinki 120
Istanbul 113
Dallas 111
Ho Chi Minh City 111
Munich 106
Fairfield 104
Milan 83
São Paulo 76
Princeton 75
Dublin 71
Frankfurt am Main 69
Buffalo 67
Redondo Beach 61
Moscow 60
Hanoi 57
Chicago 56
Romola 55
Houston 49
Council Bluffs 48
Shanghai 46
San Francisco 44
Orem 42
Woodbridge 40
Seattle 36
Wilmington 35
Montreal 33
Santa Clara 33
Cambridge 32
Tokyo 32
London 30
Brescia 29
Brooklyn 29
Jacksonville 29
Atlanta 28
Chennai 28
Brno 26
Rome 25
Warsaw 25
Boston 24
Turku 24
Guangzhou 23
Ann Arbor 22
Haiphong 21
Washington 20
Nuremberg 19
Poplar 19
Johannesburg 18
Lappeenranta 18
Belo Horizonte 17
Denver 17
Phoenix 17
Stockholm 17
Toronto 17
Brasília 16
Düsseldorf 16
Amsterdam 15
City of London 14
Porto Alegre 14
Rio de Janeiro 14
Turin 14
Dhaka 13
Hangzhou 13
Mumbai 13
Baghdad 12
Charlotte 12
Da Nang 12
Kilburn 12
Vienna 12
Biên Hòa 11
Buenos Aires 11
Curitiba 11
Erbil 11
Manchester 11
Naples 11
Salt Lake City 11
Salvador 11
Trieste 11
Las Vegas 10
Nairobi 10
Querétaro 10
Riyadh 10
Ankara 9
Campinas 9
Catania 9
Kyiv 9
Mexico City 9
Newark 9
Brussels 8
Cape Town 8
Changsha 8
Totale 6.125
Salva come PNG Salva come JPEG
Nome #
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy 188
2024 update in heart failure 171
August 2020 at a glance: focus on neurohormonal antagonists and electrolytes 153
Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study 135
In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department 134
Acute heart failure: More questions than answers 132
Clinical characteristics and outcome of acute heart failure patients with mid-range ejection fraction. 127
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) 120
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC 117
The prognostic value of serial troponin measurements in patients admitted for COVID-19 116
Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care 114
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 112
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure 111
COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease 110
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 108
Highlights in heart failure 108
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 106
Changes in Right Ventricular-to-Pulmonary Artery Coupling After Transcatheter Edge-to-Edge Repair in Secondary Mitral Regurgitation 106
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF 106
Review: Evidence-Based Management of Acute Heart Failure 106
Congestion in Patients with Advanced Heart Failure: Assessment and Treatment 101
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 101
Prediction of mortality and heart failure hospitalisations in patients undergoing M-TEER: external validation of the COAPT risk score 100
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 97
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 95
Impact of COVID-2019 outbreak on prevalence, clinical presentation and outcomes of ST-elevation myocardial infarction 94
[Sodium-glucose cotransporter 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies] 93
Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation 93
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 92
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors 92
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 92
Prognostic impact of the updated 2018 HFA-ESC definition of advanced heart failure: results from the HELP-HF registry 91
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 90
COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae 89
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice 89
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk 89
Prognostic significance of serum potassium in patients hospitalized for acute heart failure 88
April 2022 at a glance: focus on prevention, acute heart failure and heart failure with preserved ejection fraction 88
[Transcatheter devices for chronic heart failure: state of the art] 88
[Empagliflozin and heart failure: the EMPEROR-Reduced trial] 87
Telemedicine for the treatment of heart failure: new opportunities after COVID-19 87
Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration 87
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 87
Prognostic value of right ventricular longitudinal strain in patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge mitral valve repair 86
Characteristics and outcomes of patients with tricuspid regurgitation and advanced heart failure 86
Frailty according to the 2019 HFA-ESC definition in patients at risk for advanced heart failure: Insights from the HELP-HF registry 85
[Diagnostic-therapeutic care pathways for patients with cardiac amyloidosis - SIC/ANMCO Consensus document. Edited by the Italian Cardiac Amyloidosis Network (RIAC)] 85
August 2021 at a glance: focus on cardiomyopathies, medical treatment and devices 85
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials 85
July 2020 at a glance: focus on imaging and cardiomyopathies 85
Cardiac contractility modulation: an effective treatment strategy for heart failure beyond reduced left ventricular ejection fraction? 84
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 83
A year in heart failure: an update of recent findings 83
Predicting survival in patients with severe heart failure: Risk score validation in the HELP-HF cohort 83
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 83
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines 82
Impact of malnutrition in patients with severe heart failure 82
July 2021 at a glance: focus on blood volume distribution, haemodynamics and adherence to therapy 81
Heart failure: an update from the last years and a look at the near future 80
Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond - major changes are coming 79
Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC 79
September 2020 at a glance: focus on heart failure with preserved ejection fraction and medical therapy 78
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality 77
Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 76
Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry 76
Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials 75
Coronavirus disease 2019 and cardiovascular disease: what we have learnt during the last 2 years 74
Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus-A New Indication? A Meta-summary of Case Reports. 74
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy 73
Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure 73
Heart failure in the last year: progress and perspective 72
Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure 71
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trial 71
Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial 70
Impact of Pulmonary Hypertension on Outcomes after Transcatheter Tricuspid Valve Edge-to-Edge Repair 69
August 2022 at a glance: focus on heart failure with preserved ejection fraction and cardiac amyloidosis 69
April 2023 at a glance: focus on diagnosis and comorbidities 68
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists 68
Multimodality imaging in the diagnostic management of concomitant aortic stenosis and transthyretin-related wild-type cardiac amyloidosis 67
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis 67
Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation 66
September 2021 at a glance: focus on biomarkers, sex differences and adherence to medical treatment 66
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration 66
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 64
Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population 63
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial 63
Ischemic Etiology in Advanced Heart Failure: Insight from the HELP-HF Registry 63
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial 62
Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis 62
Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction 62
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction 61
Management of hypertrophic cardiomyopathy 61
Clinical burden and predictors of non-cardiovascular mortality and morbidity in advanced heart failure 61
Detailed Assessment of the "I Need Help" Criteria in Patients With Heart Failure: Insights From the HELP-HF Registry 60
NT-proBNP and high-intensity care for acute heart failure: the STRONG-HF trial 60
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 60
January 2022 at a glance: time for the new ESC guidelines on heart failure 58
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction 58
Addressing comorbidities in heart failure: When feeling better and living longer go in the same direction 58
January 2023 at a glance: focus on acute heart failure and medical therapy 57
Totale 8.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.385
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.385
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022202 4 41 4 6 8 6 8 10 14 10 18 73
2022/2023486 59 36 8 18 36 137 7 32 73 15 31 34
2023/20241.152 59 13 106 90 74 136 82 23 278 38 43 210
2024/20252.595 21 28 95 247 247 229 283 124 212 271 486 352
2025/20266.020 567 767 480 871 502 377 727 306 408 495 339 181
2026/202794 94 0 0 0 0 0 0 0 0 0 0 0
Totale 10.926